Drug intelligence / Profile preview

naltrexone + olanzapine

Development stage
Preclinical
Lead developer
Teva Pharmaceutical Industries
Modality
Small Molecules
Administration
Oral
01

Overview

Naltrexone + olanzapine is a combination of an opioid receptor antagonist (naltrexone) and an atypical antipsychotic (olanzapine). This combination has been studied as a potential approach to mitigate the significant weight gain and metabolic disturbances associated with olanzapine treatment while maintaining its antipsychotic efficacy. Naltrexone acts as a pure opioid antagonist with high affinity for μ-opioid receptors, which may be involved in feeding behavior and metabolism. While clinical studies have shown that this combination can significantly decrease fat mass and increase fat-free mass, it has not demonstrated significant effects on overall weight or BMI reduction compared to olanzapine alone.

02

Targets

DOR (Opioid Receptor Delta 1)DRD2 (Dopamine D2 Receptor)KOR (Kappa opioid receptor)MOR (Mu opioid receptor)HTR2A (Serotonin receptor 5-HT2A)

Beyond the preview

Go deeper on naltrexone + olanzapine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on naltrexone + olanzapine.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call